🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.370
+0.020 (1.48%)
Nov 18, 2026, 9:36 AM EST - Market open

ADC Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
84.8781.3670.8469.56209.9133.92
Revenue Growth
12.85%14.85%1.84%-66.86%518.89%-
Cost of Revenue
77.52107.52114.06129.66189.76159.4
Gross Profit
7.35-26.16-43.23-60.120.15-125.48
Selling, General & Admin
86.2379.9385.91105.89143.49136.24
Operating Expenses
86.2379.9385.91105.89143.49136.24
Operating Income
-78.88-106.1-129.14-165.99-123.34-261.72
Interest Expense
-52.6-51.63-50.21-46.33-36.73-18.34
Interest & Investment Income
7.788.8112.2710.542.570.07
Earnings From Equity Investments
---1.54-5.53-10.08-6.67
Currency Exchange Gain (Loss)
0.02-0.67-0.08-0.05-0.110.05
Other Non Operating Income (Expenses)
46.0823.3812.546.452.9135.11
EBT Excluding Unusual Items
-77.6-126.2-156.16-200.95-114.79-251.51
Merger & Restructuring Charges
-9.5-13.12----
Asset Writedown
4.96-2.28-1.52---
Other Unusual Items
0.5----42.11-
Pretax Income
-81.65-141.61-157.68-200.95-156.9-251.51
Income Tax Expense
-0.41.020.1739.110.23-21.48
Net Income
-81.25-142.62-157.85-240.05-157.13-230.03
Net Income to Common
-81.25-142.62-157.85-240.05-157.13-230.03
Net Income Growth
------
Shares Outstanding (Basic)
15412797827877
Shares Outstanding (Diluted)
15412797827877
Shares Change
32.81%30.78%18.91%4.55%1.83%17.33%
EPS (Basic)
-0.53-1.12-1.62-2.94-2.01-3.00
EPS (Diluted)
-0.53-1.12-1.62-2.94-2.01-3.00
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-100.55-141.44-124.7-121.9-139-236.81
Free Cash Flow Per Share
-0.65-1.11-1.28-1.49-1.78-3.09
Gross Margin
8.66%-32.16%-61.02%-86.40%9.60%-
Operating Margin
-92.94%-130.41%-182.30%-238.63%-58.76%-771.65%
Profit Margin
-95.73%-175.31%-222.83%-345.11%-74.86%-678.20%
Free Cash Flow Margin
-118.47%-173.85%-176.04%-175.25%-66.22%-698.20%
EBITDA
-78.35-105.39-127.8-164.8-122.28-260.75
EBITDA Margin
-92.32%-129.54%-180.42%-236.92%-58.26%-
D&A For EBITDA
0.530.711.331.191.060.97
EBIT
-78.88-106.1-129.14-165.99-123.34-261.72
EBIT Margin
-92.94%-130.41%-182.30%-238.63%-58.76%-
Revenue as Reported
84.8781.3670.8469.56209.9133.92
SEC Filings: 10-K · 10-Q